Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease

被引:24
作者
Wang, Jing [1 ]
Ai, Xiao-Bo [2 ]
Wang, Fei [1 ]
Zou, Yao-Wu [3 ]
Li, Li [1 ]
Yi, Xiao-Lei [4 ]
机构
[1] Qingdao Univ, Dept Endocrinol & Metab, Affiliated Hosp, Qingdao 266100, Shandong, Peoples R China
[2] Qingdao Fifth Peoples Hosp, Dept Nephrol, Qingdao, Peoples R China
[3] Heze Hosp Tradit Chinese Med, Dept Endocrinol, Heze, Peoples R China
[4] Shanghai Jiao Tong Univ, Dept Ultrasound Imaging, Peoples Hosp 6, Shanghai, Peoples R China
关键词
Ezetimibe; Atorvastatin calcium; Carotid stenosis; Type 2 diabetes mellitus; AVERAGE CHOLESTEROL LEVELS; PLACEBO-CONTROLLED TRIAL; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; PREVENTION; MEN; PRAVASTATIN; ULTRASOUND; INHIBITOR; MORTALITY;
D O I
10.23736/S0392-9590.17.03818-4
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
BACKGROUND: The aim of this study was to evaluate the efficacy of ezetimibe combined with atorvastatin in treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease (CHD). METHODS: A total of 100 patients with carotid atherosclerosis (CAS) confirmed by ultrasound and diagnosed with type 2 diabetes mellitus and CHD were randomly assigned to atorvastatin group (atorvastatin 20 mg/day) or combined treatment group (ezetimibe 10 mg/day and atorvastatin 20 mg/day). All those patients were followed for 12 months. Serum lipid, ALT, AST, and CK were measured before and after treatment. Ultrasonography was used to evaluate the stability of carotid artery plaques. RESULTS: After 12 months of treatment, the level of TC, TG, LDL-C, hs-CRP, FPG and HbA1c decreased in both groups compared with before treatment. TC, TG, LDL-C and hs-CRP in the combined treatment group were much lower than that in the atorvastatin group (P<0.05). The IMT and plaque area in the two groups were lower than that before the treatment (P<0.05). IMT and plaques area in the combined treatment group is much lower than that in the atorvastatin group after treatment. There was no significant difference in two groups on the level of ALT, AST, CK compared with baseline after treatment. CONCLUSIONS: The effect of combined use of atorvastatin and ezetimibe was better than atorvastatin alone, which can effectively reduce the blood lipid levels in diabetic patients with CHD and improve plaque stability. Both treatment regimens were safe and well tolerated.
引用
收藏
页码:467 / 473
页数:7
相关论文
共 24 条
[11]   ULTRASOUND AND BIOCHEMICAL DIAGNOSTIC TOOLS FOR THE CHARACTERIZATION OF VULNERABLE CAROTID ATHEROSCLEROTIC PLAQUE [J].
Lechareas, Simeon ;
Yanni, Amalia E. ;
Golemati, Spyretta ;
Chatziioannou, Achilles ;
Perrea, Despoina .
ULTRASOUND IN MEDICINE AND BIOLOGY, 2016, 42 (01) :31-43
[12]   Differences between Western and Asian type 2 diabetes patients in the incidence of vascular complications and mortality: A systematic review of randomized controlled trials on lowering blood glucose [J].
Li, Jing ;
Dong, Yajie ;
Wu, Taixiang ;
Tong, Nanwei .
JOURNAL OF DIABETES, 2016, 8 (06) :824-833
[13]  
Molinari F, 2012, INT ANGIOL, V31, P42
[14]   Statins Modulate Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 in Human Hepatic Myofibroblasts [J].
Mouawad, Charbel A. ;
Mrad, May F. ;
El-Achkar, Ghewa A. ;
Abdul-Sater, Ali ;
Nemer, Georges M. ;
Creminon, Christophe ;
Lotersztajn, Sophie ;
Habib, Aida .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2016, 117 (05) :1176-1186
[15]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[16]  
Pinto A, 2007, INT ANGIOL, V26, P266
[17]   Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein [J].
Ridker, Paul M. ;
Danielson, Eleanor ;
Fonseca, Francisco A. H. ;
Genest, Jacques ;
Gotto, Antonio M., Jr. ;
Kastelein, John J. P. ;
Koenig, Wolfgang ;
Libby, Peter ;
Lorenzatti, Alberto J. ;
MacFadyen, Jean G. ;
Nordestgaard, Borge G. ;
Shepherd, James ;
Willerson, James T. ;
Glynn, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (21) :2195-2207
[18]   The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels [J].
Sacks, FM ;
Pfeffer, MA ;
Moye, LA ;
Rouleau, JL ;
Rutherford, JD ;
Cole, TG ;
Brown, L ;
Warnica, JW ;
Arnold, JMO ;
Wun, CC ;
Davis, BR ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1001-1009
[19]  
Sapienza P, 2014, INT ANGIOL, V33, P530
[20]   PREVENTION OF CORONARY HEART-DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA [J].
SHEPHERD, J ;
COBBE, SM ;
FORD, I ;
ISLES, CG ;
LORIMER, AR ;
MACFARLANE, PW ;
MCKILLOP, JH ;
PACKARD, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) :1301-1307